Microsoft word - item_6_1_attachment_1_2010draftprohibitedlist_eng_final.doc
AGENDA ITEM # 6.1 ATTACHMENT 1 PROHIBITED LIST INTERNATIONAL STANDARD
The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.
This List shall come into effect on 1 January 2010 AGENDA ITEM # 6.1 ATTACHMENT 1 THE 2010 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2010
All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3.
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS
Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS)
prostanozol (17β-hydroxy-5α-androstano[3,2-c] pyrazole); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone and other substances with a similar chemical structure or similar
biological effect(s).
b. Endogenous** AAS when administered exogenously: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers:
2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally.
** “endogenous” refers to a substance which is capable of being produced by the body naturally. S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES
The following substances and their releasing factors are prohibited:
1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (dEPO), methoxy polyethylene glycol-epoetin beta (CERA), hematide]; AGENDA ITEM # 6.1 ATTACHMENT 1 2. Chorionic Gonadotrophin (CG),and Luteinizing Hormone (LH) in 3. Insulins; 4. Corticotrophins; 5. Growth Hormone (GH); Insulin-like Growth Factor-1 (IGF-1), Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF), Fibroblast Growth Factors (FGFs), Vascular-Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching; 6. Platelet-derived preparations (e.g. Platelet Rich Plasma, “blood spinning”) administered by intramuscular route. Other routes of administration require a declaration of Use according to the International
Standard for Therapeutic Use Exemptions. and other substances with similar chemical structure or similar biological effect(s).
S3. BETA-2 AGONISTS
All beta-2 agonists (including both optical isomers where relevant) are prohibited except
salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol by inhalation which require a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions.
The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an
intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the
abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol.
AGENDA ITEM # 6.1 ATTACHMENT 1
S4. HORMONE ANTAGONISTS AND MODULATORS The following classes are prohibited: 1. Aromatase inhibitors including, but not limited to: anastrozole, 4- androstene-3,6,17 trione (6-oxo), androsta-1,4,6-triene-3,17-dione (androstatrienedione), letrozole, aminoglutethimide, exemestane, formestane, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not
limited to: raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors. S5. DIURETICS AND OTHER MASKING AGENTS
Masking agents are prohibited. They include: Diuretics, probenecid, plasma expanders (e.g. glycerol; intravenous
administration of albumin, dextran, hydroxyethyl starch and mannitol) and other substances with similar biological effect(s).
Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar
biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited). A Therapeutic Use Exemption for diuretics and masking agents is not valid if an Athlete’s urine contains such substance(s) in association with threshold or sub- threshold levels of an exogenous Prohibited Substance(s). AGENDA ITEM # 6.1 ATTACHMENT 1 PROHIBITED METHODS
M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous
blood or red blood cell products of any origin.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including
but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
M2. CHEMICAL AND PHYSICAL MANIPULATION
1. Tampering, or attempting to tamper, in order to alter the integrity and
validity of Samples collected during Doping Controls is prohibited. These include but are not limited to catheterisation, urine substitution and/or adulteration (e.g. proteases).
2. Intravenous infusions are prohibited except for those legitimately received in
the course of hospital admissions or clinical investigations.
M3. GENE DOPING
The following, with the potential to enhance athletic performance, are prohibited:
1- The transfer of cells or genetic elements (e.g. DNA, RNA); 2- The use of pharmacological or biological agents that alter gene expression.
Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited. AGENDA ITEM # 6.1 ATTACHMENT 1 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition: PROHIBITED SUBSTANCES S6. STIMULANTS
All stimulants (including both optical isomers where relevant) are prohibited,
except imidazole derivatives for topical use and those stimulants included in the 2010 Monitoring Program*. Stimulants include: a: Non Specified Stimulants:
Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; methylhexaneamine (dimethylpentylamine); modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane. A stimulant not expressly listed in this section is a Specified Substance. b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamphetamine; meclofenoxate; methylephedrine****; methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tuaminoheptane and other substances with a similar chemical structure or AGENDA ITEM # 6.1 ATTACHMENT 1
* The following substances included in the 2010 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances.
** Adrenaline associated with local anaesthetic agents or by local administration
(e.g. nasal, ophthalmologic) is not prohibited.
*** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
**** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.
***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7. NARCOTICS
The following narcotics are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.
S8. CANNABINOIDS
Natural or synthetic Δ9-tetrahydrocannabinol (THC) and THC-like cannabinoids (e.g. hashish, marijuana, HU-210) are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.
In accordance with the International Standard for Therapeutic Use Exemptions, a declaration of Use must be completed by the Athlete for glucocorticosteroids administered by intraarticular, periarticular, peritendinous, epidural, intradermal and inhalation routes, except as noted below. Topical preparations when used for auricular, buccal, dermatological (including iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not prohibited and neither require a Therapeutic Use Exemption nor a declaration of use.
AGENDA ITEM # 6.1 ATTACHMENT 1 SUBSTANCES PROHIBITED IN PARTICULAR P1. ALCOHOL
Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L. Aeronautic (FAI)
P2. BETA-BLOCKERS
Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports.
Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.
Bibliografia L’Allemand, D., U. Eiholzer, M. Schlumpf, H. Steiner, W. Riesen. 2000. ’Cardiovascular risk factors improve under 3 years of GHT in Prader-Willi syndrome.’ Eur J Pediatr 159: 835-842. Aughton, D. & S. B. Cassidy. 1990. Physical features of Prader-Willi syndrome in neonates.’ Beccaria, L., F. Benzi, A. Sanzari, L. Bossio, P. Brambilla, G. Ghiumello. 1996. ‘Impairmen
Farafenni Demographic Surveillance System (Member of the INDEPTH Network) Profile of the FARAFENNI DSS, THE GAMBIA March, 2004 1. Physical geography and Population Characteristics of the Farafenni DSA The Gambia is the smallest continental country in Africa, with a land area of just 10 360 km2 (480 km from east to west and on average 48 km from north to south)
AGENDA ITEM # 6.1